Atrion Corporation (NASDAQ:ATRI) is scheduled to announce its earnings results after the market closes on Wednesday, November 1st.

Atrion Corporation (NASDAQ:ATRI) last announced its quarterly earnings results on Tuesday, August 8th. The medical instruments supplier reported $5.40 earnings per share (EPS) for the quarter. The firm had revenue of $36.16 million during the quarter. Atrion Corporation had a return on equity of 18.67% and a net margin of 22.75%. On average, analysts expect Atrion Corporation to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Atrion Corporation (ATRI) opened at 649.95 on Wednesday. The firm has a market capitalization of $1.20 billion, a P/E ratio of 36.42 and a beta of 0.92. The company has a 50-day moving average price of $664.64 and a 200-day moving average price of $604.26. Atrion Corporation has a one year low of $426.64 and a one year high of $694.00.

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 29th. Shareholders of record on Friday, September 15th were paid a dividend of $1.20 per share. This represents a $4.80 dividend on an annualized basis and a yield of 0.74%. The ex-dividend date of this dividend was Thursday, September 14th. This is a positive change from Atrion Corporation’s previous quarterly dividend of $1.05. Atrion Corporation’s dividend payout ratio (DPR) is 26.88%.

Separately, BidaskClub lowered Atrion Corporation from a “strong-buy” rating to a “buy” rating in a research note on Thursday, July 27th.

In other Atrion Corporation news, Chairman Emile A. Battat sold 1,408 shares of the firm’s stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $652.91, for a total transaction of $919,297.28. Following the completion of the sale, the chairman now owns 148,881 shares in the company, valued at approximately $97,205,893.71. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 23.10% of the stock is owned by company insiders.

WARNING: This piece of content was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at

Atrion Corporation Company Profile

Atrion Corporation (Atrion) is engaged in developing and manufacturing products, primarily for medical applications. The Company’s medical products range from fluid delivery devices to ophthalmic and cardiovascular products. Its fluid delivery products include valves that promote infection control and needle safety.

Earnings History for Atrion Corporation (NASDAQ:ATRI)

Receive News & Ratings for Atrion Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion Corporation and related companies with's FREE daily email newsletter.